ReviewCurrent hematologic malignancy reports2017
New Therapeutic Strategies in Acute Lymphocytic Leukemia.
Review in Current hematologic malignancy reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 41 citations in OpenAlex.
- Global, regional, and national epidemiology of leukemia in children from 1990 to 2021: A cross-sectional study.Medicine · 2026Article
- From cell lines to PDXs: in vivo confirmation of synergistic drug responses identified in leukemia cell line models.Blood neoplasia · 2026Article
- Inotuzumab Ozogamicin in Clinical Practice: an Overview of Efficacy, Safety, and Real-World Applications.Current hematologic malignancy reports · 2026Review
- An antibody-drug conjugate targeting VpreB1 for the treatment of B-cell acute lymphoblastic leukemia.Blood neoplasia · 2025Article
- Global, regional, and national burdens of leukemia from 1990 to 2019: A systematic analysis of the global burden of disease in 2019 based on the APC model.Cancer medicine · 2024Article
- Blinatumomab in Practice.Current hematologic malignancy reports · 2024Review
- Immunogenic Cell Death in Hematological Malignancy Therapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023Review
- The feasibility of PETHEMA ALL-96 regimen on treatment of patients with acute lymphoid leukemia.Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences · 2023Article
- The Cooperative Anti-Neoplastic Activity of Polyphenolic Phytochemicals on Human T-Cell Acute Lymphoblastic Leukemia Cell Line MOLT-4 In Vitro.International journal of molecular sciences · 2022Article
- The Landscape of Exosome-Derived Non-Coding RNA in Leukemia.Frontiers in pharmacology · 2022Review
- Targeting the lncRNA DUXAP8/miR-29a/Frontiers in oncology · 2022Article
- miR-148a-3p suppresses the progression of acute myeloid leukemia via targeting cyclin-dependent kinase 6 (CDK6).Bioengineered · 2021Article
- Preclinical efficacy of prexasertib in acute lymphoblastic leukemia.British journal of haematology · 2021Article
- Article
- Analysis of the Global Burden of Disease study highlights the trends in death and disability-adjusted life years of leukemia from 1990 to 2017.Cancer communications (London, England) · 2020Article
- Splenectomy for benign and malignant hematologic pathology: Modern morbidity, mortality, and long-term outcomes.Surgery open science · 2020Article
- Review
- Targeting mTOR in Acute Lymphoblastic Leukemia.Cells · 2019Review
- CD4Journal of immunology research · 2019Review
- Successful alternative treatment for relapsed adult acute lymphoblastic leukemia with dendritic cells-cytokine-induced killer cells combined with a rituximab-based regimen.OncoTargets and therapy · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Most drugs used in standard regimens for acute lymphoblastic leukemia (ALL) were developed more than 30 years ago. Since that time, several new drugs have been developed and incorporated into ALL treatment. In spite of this, novel therapeutic approaches are still needed to improve outcomes for high-risk or relapsed ALL. This manuscript discusses newer treatment strategies, including purine nucleoside analogs, monoclonal antibodies, antibody drug conjugates, mammalian target of rapamycin (mTOR) inhibitors, proteasome inhibitors, histone deacetylase (HDAC) inhibitors, hypomethylating agents, spleen tyrosine kinase inhibitors, Bruton's tyrosine kinase (BTK) inhibitors, Janus kinase-signal transducer and activator of transcription (JAK-STAT) inhibitors, anti-programmed cell death protein (anti-PD-1) antibodies, mitogen-activated protein kinase (MEK) inhibitors, CXCR4 antagonists, poly (ADP-ribose) polymerase (PARP) inhibitors, and FMS-like tyrosine kinase 3 (FLT3) inhibitors. Additionally, this manuscript discusses the impact of diagnostic approaches on management of ALL. Specifically, minimal residual disease is increasingly felt to be important and will likely dramatically impact the care of ALL patients in the near future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.